To the content

AOP Orphan Statement on SARS-CoV-2 and COVID-19

March 17th 2020
Vienna, March 17, 2020: On Wednesday March 11 the World Health Organization (WHO) announced a pandemic in response to the COVID-19 outbreak. This is a serious health situation influencing numerous countries worldwide. We want to express our deepest sympathy for those who are affected, their relatives and healthcare professionals who work hard to improve current situation.

As COVID-19 continues to spread these days, our primary concern is the health and safety of our employees and patients globally. It is of a vital importance for us to set up the measures to protect them and to ensure further regular operations of AOP Orphan in all countries.

With that in mind, we have implemented following actions effective as from Monday, March 16 to April 30, 2020:

  • General travel restrictions for all AOP Orphan employees.
  • AOP Orphan Meetings are to be conducted digitally.
  • All AOP Orphan employees are requested to work from home, except those who work in the departments that are of a core importance for company’s operations, e.g. Supply Chain Management, Drug Safety and Quality Assurance.
  • Internal guidance on how our employees can protect themselves against coronavirus infection.
  • Enacting plans to ensure further ongoing drug supply in all countries. We are working closely with local health authorities and governmental representatives as well as with our product manufacturers and distributors in affected countries to ensure that patients get access to the drugs without interruptions.
Portrait von Andreas Steiner, CEO AOP Health
Portrait von Andreas Steiner, CEO AOP Health
Andreas Steiner

We are monitoring the development of this situation daily and do our utmost to secure continued uninterrupted supply of our medicines and services to patients around the world. At this stage we do not anticipate any product shortages.

About AOP Health

The brand AOP Health incorporates several companies: The international Healthcare Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the company has become an established provider of integrated therapy solutions from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all our stakeholders on the other - especially the patients and their families as well as also the doctors and care professionals treating them. 


Press Contact.

Mag. Nina Roth, MAS

Head of Corporate Communications

To the main navigation